Impact of switching from double-blind placebo or entacapone to open-label opicapone in UPDRS-II and III scores in the open-label 1-year extension BIPARK-I study

被引：0
|
作者：
Ehret, R. -M. [1 ]
Ferreira, J. [2 ]
Stocchi, F. [3 ]
Ikedo, F. [4 ]
Arbe, E. [5 ]
Rocha, J. [5 ]
Soares-Da-Silva, P. [4 ]
机构：
[1] Neurol Berlin, Berlin, Germany
[2] Inst Med Mol, Neurol Clin Res Unit, Lisbon, Portugal
[3] IRCCS San Rafaelle Pisana, Rome, Italy
[4] BIAL Portela & Ca SA, R&D Dept, Coronado, Portugal
[5] BIAL Portela & Ca SA, Global Parkinson Dis, Coronado, Portugal
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2019年 / 26卷
关键词：
MOTOR FLUCTUATIONS; LEVODOPA; DISEASE; ADJUNCT;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO1194
引用
收藏
页码：462 / 462
页数：1
相关论文
共 50 条
  • [1] Switching from double-blind entacapone or placebo to open-label opicapone: UPDRS-II and III results of the 1-year extension BIPARK-I study
    Ehret, R.
    Ferreira, J.
    Stocchi, F.
    Ikedo, F.
    Arbe, E.
    Rocha, J-F.
    Soares-da-Silva, P.
    MOVEMENT DISORDERS, 2018, 33 : S102 - S102
  • [2] Switching from double-blind entacapone or placebo to open-label opicapone: UPDRS-II and III results from patients who ended 1-year BIPARK-I extension on opicapone 50 mg
    Rocha, F.
    Ferreira, J.
    Lees, A.
    Tolosa, E.
    Stocchi, F.
    Santos, A.
    Magalhaes, D.
    Soares-da-Silva, P.
    Savic, N.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [3] SWITCHING FROM DOUBLE-BLIND ENTACAPONE OR PLACEBO TO OPEN-LABEL OPICAPONE: NMSS RESULTS (1-YEAR EXTENSION BIPARK-I STUDY)
    Fabregues, O.
    Tolosa, E.
    Ferreira, J.
    Lees, A.
    Santos, A.
    Rocha, J.
    Soares-Da-Silva, P.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2019, 90 (12): : E49 - E49
  • [4] Switching from double-blind entacapone or placebo to open-label opicapone: NMSS results of the 1-year extension BIPARK-I study
    Fabregues, O.
    Tolosa, E.
    Ferreira, J.
    Lees, A.
    Santos, A.
    Arbe, E.
    Rocha, J-F.
    Soares-da-Silva, P.
    MOVEMENT DISORDERS, 2018, 33 : S142 - S142
  • [5] Switching entacapone or placebo to opicapone Open-label: Efficacy results of the BIPARK-I 1-year extension
    Ferreira, J.
    Lees, A.
    Rascol, O.
    Poewe, W.
    Santos, A.
    Ikedo, F.
    Oliveira, I.
    Rocha, J. F.
    Soares-da-Silva, P.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 725 - 726
  • [6] Switching double-blind opicapone, entacapone or placebo to open-label opicapone: Efficacy results of the 1-year extension of study BIPARK I
    Ferreira, J.
    Lees, A.
    Tolosa, E.
    Poewe, W.
    Santos, A.
    Lopes, N.
    Rocha, J. F.
    Soares-da-Silva, P.
    MOVEMENT DISORDERS, 2016, 31 : S633 - S633
  • [7] Switch of double-blind opicapone, entacapone or placebo to open-label opicapone: efficacy results of the 1-year extension of study BIPARK I
    Ferreira, J.
    Lees, A.
    Tolosa, E.
    Poewe, W.
    Banach, M.
    Santos, A.
    Lopes, N.
    Rocha, J. F.
    Soares-Da-Silva, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 393 - 393
  • [8] Impact of switching from double-blind placebo or entacapone to open-label opicapone in non-motor symptoms scale: results from the 1-year extension BIPARK-I study
    Fabregues, O.
    Tolosa, E.
    Ferreira, J.
    Lees, A.
    Santos, A.
    Rocha, J.
    Soares-Da-Silva, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 465 - 465
  • [9] Switching from double-blind entacapone or placebo to open-label opicapone: change in OFF-/ON-time from patients who ended the 1-year BIPARK-I extension on opicapone 50 mg
    Ferreira, J.
    Lees, A.
    Rascol, O.
    Poewe, W.
    Ikedo, F.
    Magalhaes, D.
    Rocha, F.
    Soares-da-Silva, P.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [10] Change in OFF-/ON-Time After Switching from Double-Blind Entacapone or Placebo to Open-Label Opicapone in Patients who Ended the 1-Year BIPARK-I Extension Study on Opicapone 50mg
    Poewe, W.
    Ferreira, J. J.
    Lees, A.
    Rascol, O.
    Ikedo, F.
    Magalhaes, D.
    Rocha, J. -F.
    Soares-Da-Silva, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 1101 - 1102
12345